Drugs / HS632
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04361812 | Oct 2020 → Dec 2021 | — | BioRay Pharmaceutical Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS632 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04361812 ↗ |
| Modality | Monoclonal antibody | “recombinant anti IgE humanized monoclonal antibody (HS632)” NCT04361812 ↗ |
| Route | Subcutaneous | “Subcutaneous injection of HS632” NCT04361812 ↗ |